Back

Efficacy and safety of direct oral anticoagulants in patients with device-detected atrial fibrillation with and without dose reduction criteria: a pooled analysis of ARTESiA and NOAH-AFNET 6

29 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: The atrial fibrillation anticoagulation puzzle: putting the pieces together Stroke in Atrial Fibrillation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor William McIntyre

Population Health Research Institute, Hamilton (Canada)

7 More presentations in this session

Presentation thumbnail
Peridevice leak and device-related thrombus in the OPTION randomized trial
Doctor O. wazni (Cleveland, US)
Abstract Slides
Presentation thumbnail
Impact of anaemia on OAC prescription and adverse outcomes in patients with AF and chronic HF: an analysis form a real-world observational prospective study
Doctor M. Vitolo (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Discontinuation of oral anticoagulation and risk of worse clinical outcomes in atrial fibrillation patients: a report from the Murcia AF Project III
Doctor J. Rivera-Caravaca (Murcia, ES)
Abstract Slides Video
Presentation thumbnail
Impact of Clinical Complexity Features on the Risk of Major Bleeding and Subsequent Outcomes in Atrial Fibrillation Patients: A Multistate Model analysis from Two Large Observational Registries
Doctor D. Mei (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Comparative in-hospital outcomes of acute ischemic stroke by preexisting atrial flutter or atrial fibrillation, stratified by CHADSVA score
Doctor A. Folman (Hadera, IL)
Abstract Slides Video

Access the full session

Session thumbnail
The atrial fibrillation anticoagulation puzzle: putting the pieces together

The Event

Event poster

ESC Congress 2025

29 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial. - discussion
9 April 2024
thumbnail
Congress Presentation
Impact of different dose reduction criteria on dose assignment of current DOACs and related outcomes: an analysis from 4-year data of the ETNA-AF Europe programme
8 April 2024
thumbnail
Congress Presentation
Comparing the efficacy and safety of DOACs with VKAs in patients with end-stage kidney disease on dialysis and non-valvular atrial fibrillation: a systematic review and meta-analysis
31 August 2025
thumbnail
Congress Session
The clinical continuum of atrial fibrillation: balancing risks to optimise outcomes
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources